Search Results

• • 141 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells

  Authors:John P Vanden Heuvel, Ewa Maddox, Samar W Maalouf, Elizabeth Iorns, Rachel Tsui, Alexandria Denis, et al.From:eLife (Vol. 7) Peer-Reviewed

  Jan. 9, 20188,803 words Report 1520LIn 2016, as part of the Reproducibility Project: Cancer Biology (https://osf.io/e81xl/wiki/home/), we published a Registered Report (Vanden Heuvel et al., 2016), that described how we intended to replicate selected...

• Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer.

  Author:Rebecca PrevisFrom:Oncology (Vol. 35, Issue 4) Peer-Reviewed

  Apr. 20212,687 words Article 1740LOvarian cancer is the fifth most common cause of cancer deaths in women and the leading cause of death among cancers of the female reproductive system in the United States. More than 21,400 women in the United States are...

• A review on mechanisms of resistance to PARP inhibitors.

  Authors:Chirag Desai, Anand Pathak, Sewanti Limaye, Vashishth Maniar, and Archita JoshiFrom:Indian Journal of Cancer (Vol. 59, Issue 5) Peer-Reviewed

  Mar. 20226,635 words Article 1850LByline: Chirag. Desai, Anand. Pathak, Sewanti. Limaye, Vashishth. Maniar, Archita. Joshi Standard therapy for advanced ovarian cancer (OC) consists of radical debulking cytoreductive surgery followed by adjuvant...

• New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.

  Authors:Daniela Criscuolo, Francesco Morra, Riccardo Giannella, Roberta Visconti, Aniello Cerrato, and Angela CelettiFrom:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  Feb. 22, 20196,332 words Article 1680LBackground Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer...

• HPF1 and nucleosomes mediate a dramatic switch in activity of PARP1 from polymerase to hydrolase.

  Authors:Johannes Rudolph, Genevieve Roberts, Uma M Muthurajan, and Karolin LugerFrom:eLife (Vol. 10) Peer-Reviewed

  Mar. 8, 202116,866 words Article 1540LPoly(ADP-ribose) polymerase 1 (PARP1) is an important player in the response to DNA damage. Recently, Histone PARylation Factor (HPF1) was shown to be a critical modulator of the activity of PARP1 by facilitating...

• Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations.

  Authors:Shouki Bazarbashi, Abdullah Alsharm, Alaa Meshref, Hind Mrabti, Jawaher Ansari, Marwan Ghosn, et al.From:Urology Annals (Vol. 14, Issue 4) Peer-Reviewed

  Oct-Dec 20225,335 words Article 1830LByline: Shouki. Bazarbashi, Abdullah. Alsharm, Alaa. Meshref, Hind. Mrabti, Jawaher. Ansari, Marwan. Ghosn, Mohamed. Abdulla, Yuksel. Urun Despite the reliance on Western guidelines for managing prostate cancer (PC),...

• Sonicated Extract from the Aril of Momordica Cochinchinensis Inhibits Cell Proliferation and Migration in Aggressive Prostate Cancer Cells.

  Authors:Seksom Chainumnim, Sunit Suksamrarn, Faongchat Jarintanan, Suchada Jongrungruangchok, Sivaporn Wannaiampikul, and Wanlaya TanechpongtambFrom:Journal of Toxicology (Vol. 2022) Peer-Reviewed

  Dec. 27, 20227,590 words Article 1310LMomordica cochinchinensis or gac fruit has been reported to have several biological activities, including antioxidation, anti-inflammatory, and anticancer activities. However, the effect on cancer cell metastasis has not...

• Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

  Authors:Yi Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L. Hsu, Hung-Ling Wang, Yi-Hsin Hsu, et al.From:Nature Medicine (Vol. 22, Issue 2) Peer-Reviewed

  Feb. 20167,973 words Report 1450LPoly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials (1). One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently...

• Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early-Phase Clinical Trials.

  Authors:Rachael Galvin, Christine Chung, Ella Achenbach, Oliwier Dziadkowiec, and Shiraj SenFrom:Oncology (Vol. 34, Issue 10) Peer-Reviewed

  Oct. 20203,896 words Article 1710LBACKGROUND: Early-phase clinical trials are critical to the advancement of cancer care, especially in patients with pancreatic ductal adenocarcinoma, given its aggressive nature and limited available therapeutic options....

• Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.

  Authors:Rui Zhang, Peng Gao, Yanxi Han, Runling Zhang, Ping Tan, Li Zhou, et al.From:Breast Cancer (Vol. 28, Issue 3) Peer-Reviewed

  May 20216,250 words Clinical report 1680LBackground BRCA1/2 gene mutation testing, based on next-generation sequencing (NGS), has been gradually applied in the clinic to serve as preventive early screening for predisposed individuals or to provide treatment...

• Prostate cancer and PARP inhibitors: progress and challenges.

  Authors:Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  Mar. 29, 202110,243 words Article 1400LDespite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic...

• Novel therapies are changing treatment paradigms in metastatic prostate cancer.

  Authors:Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, et al.From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-Reviewed

  Oct. 28, 20207,543 words Article 1610LMetastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose...

• The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.

  Authors:Francesco Morra, Francesco Merolla, Giovanna Damia, Francesca Ricci, Silvia Varricchio, Gennaro Ilardi, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 41, Issue 1) Peer-Reviewed

  Aug. 13, 202210,264 words Article 1490LBackground Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair...

• PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?

  Author:Abhay GaurFrom:Indian Journal of Urology (Vol. 38, Issue 4) Peer-Reviewed

  Oct-Dec 20221,036 words Clinical report 1550LByline: Abhay. Gaur Summary The knowledge of homologous recombination repair (HRR) deficiency in certain cancer cells and the advent of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors has led to a...

• Resurrected cancer drug faces regulators

  Author:Heidi LedfordFrom:Nature (Vol. 510, Issue 7506) Peer-Reviewed

  June 26, 20141,044 words Article 1390LAuthor(s): Heidi Ledford A cancer drug once lauded as a shining example of translational research but cast aside after a disappointing clinical trial may be rising from the ashes. Olaparib was one of the first...

• Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.

  Authors:Dongju Park, Reena Shakya, Christopher Koivisto, Jason R. Pitarresi, Matthias Szabolcs, Raleigh Kladney, et al.From:PLoS ONE (Vol. 14, Issue 12) Peer-Reviewed

  Dec. 26, 20199,023 words Article 1560LAlterations of the PALB2 tumor suppressor gene have been identified in familial breast, ovarian and pancreatic cancer cases. PALB2 cooperates with BRCA1/2 proteins through physical interaction in initiation of homologous...

• Olaparib, a new hope for ovarian cancer.

  Authors:Zarka Samoon and Adnan JabbarFrom:Indian Journal of Cancer (Vol. 57, Issue 3) Peer-Reviewed

  July-Sep 20201,427 words Article 1760LByline: Zarka. Samoon, Adnan. Jabbar Ovarian cancer is the most common cause of death among gynecologic cancers and has a cure rate of less than 40% in women.[1] Around 70% of women present with advanced disease, with...

• Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.

  From:Oncology (Vol. 34, Issue 10) Peer-Reviewed

  Oct. 20201,837 words Article 1970LOvarian cancer is the leading cause of mortality among gynecologic cancers in the United States, (1) expected to result in roughly 13,940 deaths in 2020. (2) Between 2008 and 2017, mortality decreased by 2.3% per year....

• Feasibility of using pemetrexed as a salvage regimen in heavily pre-treated patients with ovarian cancer: A retrospective review.

  Authors:Peter Dottino, Matthew Dashkoff, and Ann BeddoeFrom:Indian Journal of Cancer (Vol. 57, Issue 4) Peer-Reviewed

  Oct-Dec 20201,340 words Article 1720LByline: Peter. Dottino, Matthew. Dashkoff, Ann. Beddoe Over the past three decades, survival among all patients with ovarian cancer has improved. Characteristically, however, 5-year survival from advanced epithelial...

• Pregnancy after breast cancer in BRCA1/2 mutation carriers.

  Authors:Jelena Maksimenko, Arvīds Irmejs, and Janis GardovskisFrom:Hereditary Cancer in Clinical Practice (Vol. 20, Issue 1) Peer-Reviewed

  Jan. 21, 20225,179 words Report 1600LBackground Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of...